Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-norfolk cohort

Journal of Infectious Diseases

Volumn 206, Issue 12, 2012, Pages 1897-1903

  Gkrania Klotsas, Effrossyni ^a   Langenberg, Claudia ^a   Sharp, Stephen J ^a   Luben, Robert ^b   Khaw, Kay Tee ^b   Wareham, Nicholas J ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DATA BASE; DEATH CERTIFICATE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ICD-10; ICD-9; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SOCIAL CLASS;

ADULT; AGED; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA;

EID: 84870198003     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis620     Document Type: Article

References (46)

1. Soderberg-Naucler C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001; 71:SS24-30. (Pubitemid 32566547)
2. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-6. (Pubitemid 19155945)
3. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009; 28:461-7.
4. Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: Current knowledge and future direction. Clin Transplant 2011; 25:175-84.
5. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet 1997; 350:430-6. (Pubitemid 27331246)
6. Ossewaarde JM, Feskens EJ, De Vries A, Vallinga CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120:93-9. (Pubitemid 28130026)
7. Strachan DP, Carrington D, Mendall MA, Butland BK, Sweetnam PM, Elwood PC. Cytomegalovirus seropositivity and incident ischaemic heart disease in the Caerphilly prospective heart disease study. Heart 1999; 81:248-51. (Pubitemid 29116333)
8. Coles KA, Knuiman MW, Plant AJ, Riley TV, Smith DW, Divitini ML. A prospective study of infection and cardiovascular diseases: The Busselton Health Study. Eur J Cardiovasc Prev Rehabil 2003; 10:278-82. (Pubitemid 37433493)
9. Rahel BM, Visseren FL, Suttorp MJ, et al. Cytomegalovirus and Chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention. Am Heart J 2004; 148:670-5. (Pubitemid 39349388)
10. Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131:573-7. (Pubitemid 29494087)
11. Haider AW, Wilson PWF, Larson MG, et al. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: A prospective study. J Am Coll Cardiol 2002; 40:1408-13. (Pubitemid 35192864)
12. Rothenbacher D, Brenner H, Mertens T, Hoffmann MM, Hoffmeister A, Koenig W. Prognostic value of interleukin-1 receptor antagonist gene polymorphism and cytomegalovirus seroprevalence in patients with coronary artery disease. BMC Cardiovasc Disord 2005; doi:10-1186/1471-2261-5-10.
13. Guech-Ongey M, Brenner H, Twardella D, Hahmann H, Rothenbacher D. Role of cytomegalovirus sero-status in the development of secondary cardiovascular events in patients with coronary heart disease under special consideration of diabetes. Int J Cardiol 2006; 111:98-103. (Pubitemid 44131482)
14. Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104:25-31. (Pubitemid 32623285)
15. Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000; 102:1917-23.
16. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103:45-51. (Pubitemid 32050434)
17. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: The atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160:2027-32. (Pubitemid 30437586)
18. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335:624-30. (Pubitemid 26277952)
19. Neumann FJ, Kastrati A, Miethke T, et al. Previous cytomegalovirus infection and restenosis after coronary stent placement. Circulation 2001; 104:1135-9. (Pubitemid 32830397)
20. Niu YH, Ge JB, Xu CF, et al. Impact of pathogen burden on in-stent restenosis in patients after coronary stent implantation. Chin Med J (Engl) 2005; 118:1786-90.
21. Chaubey S, Nitsch D, Altmann D, Ebrahim S. Differing effect of modifiable cardiovascular risk factors on intima-media thickening and plaque formation at different sites of the arterial vasculature. Heart 2010; 96:1579-85.
22. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98:2796-9. (Pubitemid 29003958)
23. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000; 101:252-7. (Pubitemid 30054151)
24. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The Cardiovascular Health Study. Circulation 2000; 102:2335-40.
25. Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:251-7. (Pubitemid 36135220)
26. Witherell HL, Smith KL, Friedman GD, et al. C-reactive protein, Helicobacter pylori, Chlamydia pneumoniae, cytomegalovirus and risk for myocardial infarction. Ann Epidemiol 2003; 13:170-7. (Pubitemid 36258405)
27. Arcari CM, Gaydos CA, Nieto FJ, Krauss M, Nelson KE. Association between Chlamydia pneumoniae and acute myocardial infarction in young men in the United States military: The importance of timing of exposure measurement. Clin Infect Dis 2005; 40:1123-30. (Pubitemid 40490236)
28. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999; 30:299-305. (Pubitemid 29071793)
29. Reunanen A, Roivainen M, Kleemola M, et al. Enterovirus, mycoplasma and other infections as predictors for myocardial infarction. J Intern Med 2002; 252:421-9. (Pubitemid 36706573)
30. Lammintausta A, Immonen-Raiha P, Airaksinen JK, et al. Socioeconomic inequalities in the morbidity and mortality of acute coronary events in Finland: 1988 to 2002. Ann Epidemiol 2012; 22:87-93.
31. Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol Infect 2009; 137:58-65.
32. Streblow DN, Soderberg-Naucler C, Vieira J, et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999; 99:511-20.
33. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in apolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23-8. (Pubitemid 32429591)
34. Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007; 19:577-82. (Pubitemid 47464920)
35. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: Study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999; 80(Suppl 1):95-103. (Pubitemid 29389613)
36. Wijndaele K, Brage S, Besson H, et al. Television viewing and incident cardiovascular disease: Prospective associations and mediation analysis in the EPIC Norfolk Study. PLoS One 2011; 6:e20058.
37. Guisasola ME, Ramos B, Sanz JC, Garcia-Bermejo I, De Ory Manchon F. Comparison of IgG avidity assays in the confirmation of the diagnosis of cytomegalovirus primary infection. APMIS 2010; 118:991-3.
38. Phillimore P, Beattie A, Townsend P. Widening inequality of health in northern England, 1981-91. BMJ 1994; 308:1125-8. (Pubitemid 24130972)
39. Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol 2007; 42:563-70. (Pubitemid 46756093)
40. Blum A, Giladi M, Weinberg M, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81:866-8. (Pubitemid 28204640)
41. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet No. 317. WHO Media Centre, 2011.
42. Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306:2120-7.
43. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20:202-13.
44. Ergin A, Muntner P, Sherwin R, He J. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am J Med 2004; 117:219-27. (Pubitemid 39092714)
45. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: Variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104:2855-64. (Pubitemid 33126663)
46. DiaSorin. DiaSorin MiniCD Liaison manual. LIAISON® CMV IgG (Version 310740, Saluggia, Italy).1-8.